ALIGN TECHNOLOGY INC ALGN

Align Technology entered the period with a clear signal to the market: on 1 May 2026 it filed an 8-K announcing plans to repurchase $200.0 million of common stock, the opening tranche of a $1.0 billion buyback programme already approved by its board. The same window produced a 10-Q for the quarter ending 31 March 2026 showing $1.04 billion of revenue, the two documents together framing a profitable maker of dental hardware choosing to return cash while its core pricing barely moved.

The business sells clear aligners and the scanning and software around them, a product line measured case by case. The 10-Q records clear aligner revenue per case shipment rising from $1,240 in the first quarter of 2025 to $1,250 in the first quarter of 2026, a 0.8% increase, while higher discounts and a mix shift toward lower-priced countries and products reduced net revenues by $28 million. Pricing power, in other words, is thin, and geography is doing some of the work.

The filed financials show net income attributable to the parent of $112.8 million, operating income of $142.0 million, and diluted earnings per share of $1.57 on 71.6 million weighted average diluted shares, all for the period ending 31 March 2026. The balance sheet carries $6.31 billion of assets against $2.16 billion of liabilities, leaving $4.15 billion of stockholders' equity and $1.06 billion of cash. Operating activities generated $151.0 million, capital expenditure was $30.8 million, and research and development cost $98.7 million.

There is no chart route in the supplied source rail, so this file rests entirely on SEC EDGAR documents rather than price levels or candles. The relevant mechanism is disclosure: the 10-Q, the 8-K buyback notice, a Form SD conflict minerals report dated 29 May 2026, and five Form 4 insider ownership filings dated 22 May 2026. Each is a primary record, and none of them sets a target, forecast, or valuation.

What changed is the capital decision: a cash-rich, profitable company is leaning into repurchases while per-case pricing rose by a single-digit dollar amount and inventory of $214.9 million fell by $9.3 million. What remains unproven from this evidence is the path of case volume, the durability of the mix shift to cheaper markets, and whether the buyback continues beyond its first $200.0 million. Segment detail, case shipment counts, and forward guidance would deepen the file; the current rail does not supply them.